| Aug 7 |
SpringWorks Therapeutics, Inc. 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 7 |
SpringWorks Therapeutics, Inc. (SWTX) Q2 2024 Earnings Call Transcript
|
| Aug 7 |
SpringWorks Therapeutics GAAP EPS of -$0.54 beats by $0.58, revenue of $59.73M beats by $25.15M
|
| Aug 7 |
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
| Aug 6 |
SpringWorks Therapeutics Q2 2024 Earnings Preview
|
| Jul 29 |
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
|
| Jul 23 |
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
|
| Jul 1 |
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
|
| Jun 8 |
GSK, SpringWorks end collaboration agreement
|
| Jun 6 |
Insider Sale: Director Julie Hambleton Sells Shares of SpringWorks Therapeutics Inc (SWTX)
|
